Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209882 | PMC |
| http://dx.doi.org/10.17879/freeneuropathology-2021-3639 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Combination of Conventional Transconjunctival Lower Blepharoplasty and Percutaneous Nanofat Grafting in a Young Chinese Population With Eyelid Bags and Tear Trough Deformities.
J Cosmet Dermatol
January 2025
Department of Dermatology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, People's Republic of China.
Objective: A simple and minimally invasive combined procedure, including transconjunctival orbital fat removal and transcutaneous resected orbital fat injection, was performed based on the anatomical characteristics of the lower eyelids in our young Chinese patients. Our study aimed to investigate the efficacy and safety of this procedure in our study population.
Methods: In our retrospective study, a total of 183 consecutive patients underwent a combination of traditional transconjunctival blepharoplasty and nanofat grafting between February 2020 and June 2024.
Oncological Feasibility of Limited Neck Dissection in cN0 Supraglottic Laryngeal Cancer.
Head Neck
January 2025
Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
Background: Supraglottic squamous cell carcinoma (SCC) is a significant portion of head and neck cancers, with the management of clinically negative necks (cN0) through selective neck dissection (SND) being debated due to potential morbidities and low metastasis rates in levels IIb and IV.
Methods: This study is a retrospective, multicenter examination of the potential feasibility of limited neck dissection (LND), including only levels IIa and III in cN0 supraglottic SCC patients. It analyzed occult metastasis rates and explored relapse occurrences alongside potential predictors of lymph node metastasis.
Annular Closure Device Reduces Symptomatic Reherniation Rates: Results of a Meta-analysis.
HSS J
February 2025
Department of Spine Surgery, Hospital for Special Surgery, New York, NY, USA.
The scope of existing annular closure device (ACD) studies examining long-term follow-up data is limited. There is a paucity of studies that report and analyze recent outcomes data following ACD use. We sought to summarize the available long-term follow-up data on postoperative outcomes of the Barricaid (Intrinsic Therapeutics) ACD.
View Article and Find Full Text PDFInfiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints.
Front Immunol
January 2025
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
Cholangiocarcinoma is the second most common primary liver cancer, and its global incidence has increased in recent years. Radical surgical resection and systemic chemotherapy have traditionally been the standard treatment options. However, the complexity of cholangiocarcinoma subtypes often presents a challenge for early diagnosis.
View Article and Find Full Text PDFAnalysis of the relevant factors for corneal graft rejection in the southern Liaoning region from 2019 to 2023.
Front Med (Lausanne)
January 2025
Dalian Medical University, Dalian, China.
Background: The study aimed to review the etiology of corneal blindness and investigate the relative risk of corneal graft rejection (CGR) in the southern Liaoning region.
Methods: The clinical records of 359 patients (394 eyes) who underwent corneal transplantation at the Department of Keratoconus of the Third People's Hospital of Dalian from January 2019 to December 2023 were retrospectively analyzed. The data included patients' age, gender, occupation, diagnosis, surgical procedure, postoperative immune rejection, and neovascularization.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!